Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Rady Children's Hospital
mi
from
San Diego, CA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Rady Children's Hospital
mi
from
San Diego, CA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
ALL Children's Hospital/St. Petersburg Hospital
mi
from
St. Petersburg, FL
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
ALL Children's Hospital/St. Petersburg Hospital
mi
from
St. Petersburg, FL
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children's Hospital Denver
mi
from
Aurora, CO
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital Denver
mi
from
Aurora, CO
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
University of Mississippi
mi
from
Jackson, MS
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
University of Mississippi
mi
from
Jackson, MS
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Washington University
mi
from
St. Louis, MO
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Cook Children's Health Care System
mi
from
Fort Worth, TX
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Cook Children's Health Care System
mi
from
Fort Worth, TX
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Mayo Clinic - Jacksonville, Florida
mi
from
Jacksonville, FL
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Jacksonville, Florida
mi
from
Jacksonville, FL
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Minnesota Oncology Hematology-Edina
mi
from
Edina, MN
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Minnesota Oncology Hematology-Edina
mi
from
Edina, MN
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
UW Cancer Center Johnson Creek
mi
from
Johnson Creek, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
UW Cancer Center Johnson Creek
mi
from
Johnson Creek, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Ohio State University
mi
from
Columbus, OH
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Dayton Clinical Research
mi
from
Dayton, OH
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Dayton Clinical Research
mi
from
Dayton, OH
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Willamette Valley Cancer Center
mi
from
Eugene, OR
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Willamette Valley Cancer Center
mi
from
Eugene, OR
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Texas Oncology-Tyler
mi
from
Tyler, TX
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Texas Oncology-Tyler
mi
from
Tyler, TX
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Yakima Valley Memorial
mi
from
Yakima, WA
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Yakima Valley Memorial
mi
from
Yakima, WA
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
A Phase 1 Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of Navitoclax
Status: Archived
Clinical Research Facility
mi
from
Santa Monica, CA
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
A Phase 1 Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of Navitoclax
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Monica, CA
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL